Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Spero Therapeutics, Inc. (SPRO) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Spero Therapeutics, Inc. 2017 Stock Incentive Plan, as amended",
"CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION, AS AMENDED OF SPERO THERAPEUTICS, INC.",
"Spero Therapeutics, Inc. 2017 Stock Incentive Plan, as amended"
08/10/2023 8-K Quarterly results
Docs: "Spero Therapeutics Announces Second Quarter 2023 Operating Results and Provides a Business Update"
07/31/2023 8-K Quarterly results
05/11/2023 8-K Quarterly results
Docs: "Spero Therapeutics Announces First Quarter 2023 Operating Results and Provides a Business Update"
02/01/2023 8-K Quarterly results
01/09/2023 8-K Investor presentation
Docs: "Investor Presentation of Spero Therapeutics, Inc.",
"Excerpts from Investor Presentation of Spero Therapeutics, Inc."
11/14/2022 8-K Quarterly results
11/08/2022 8-K Quarterly results
09/22/2022 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"GSK and Spero Therapeutics Announce Exclusive License Agreement for Late-Stage Antibiotic Asset, Tebipenem HBr"
09/19/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Spero Therapeutics, Inc. 2017 Stock Incentive Plan, as amended",
"Spero Therapeutics, Inc. 2017 Stock Incentive Plan, as amended"
09/06/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Media Inquiries:"
08/10/2022 8-K Quarterly results
07/01/2022 8-K Quarterly results
06/27/2022 8-K Quarterly results
06/07/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
05/03/2022 8-K Quarterly results
03/31/2022 8-K Quarterly results
Docs: "Spero Therapeutics Announces Fourth Quarter and Full Year 2021 Operating Results and Provides Business Update"
02/16/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Spero Therapeutics Announces Positive Topline Results from Phase 1 Bronchoalveolar Lavage Clinical Trial of SPR206, A Novel Intravenous Next Generation Polymyxin Antibiotic for the Treatment of Multi-drug Resistant Gram-Negative Infections in the Hospital Setting"
01/25/2022 8-K Investor presentation
Docs: "Investor Presentation of Spero Therapeutics, Inc.",
"Excerpts from Investor Presentation of Spero Therapeutics, Inc."
01/19/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Spero Therapeutics Awarded up to an Additional $12.9 Million by BARDA to Support the Development of Orally Administered Tebipenem Pivoxil in Pediatric Patients"
01/04/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Spero Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Tebipenem HBr for the Treatment of Complicated Urinary Tract Infections including Pyelonephritis",
"Spero Therapeutics Announces Lifting of FDA Clinical Trial Hold on SPR720"
11/10/2021 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Spero Therapeutics, Inc. Condensed Consolidated Statements of Operations Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Revenues: Grant revenue $ 2,356 $ 3,957 $ 12,698 $ 7,165 Collaboration revenue 708 38 2,814 $ 258 Total revenues 3,064 3,995 15,512 7,423 Operating expenses: Research and development 14,436 17,706 47,301 53,798 General and administrative 11,152 5,309 28,680 13,942 Total operating expenses 25,588 23,015 75,981 67,740 Loss from operations Other income 3 84 622 Net loss $ $ $ $ Deemed dividend $ — $ — $ — $ Net loss attributable to common shareholders of Spero Therapeutics, Inc. $ $ $ $ Net loss per share attributable to common shareholders per share, basic and diluted $ $ $ $ Weighted average shares outstanding, basic and diluted: 32..."
10/28/2021 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Vice President, Head of Investor Relations"
10/12/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Vice President, Head of Investor Relations"
09/30/2021 8-K Quarterly results
08/30/2021 8-K Quarterly results
08/18/2021 8-K Quarterly results
08/05/2021 8-K Quarterly results
Docs: "Spero Therapeutics, Inc. Condensed Consolidated Statements of Operations Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Revenues: Grant revenue $ 3,042 $ 1,676 $ 10,342 $ 3,208 Collaboration revenue 2,106 51 2,106 $ 220 Total revenues 5,148 1,727 12,448 3,428 Operating expenses: Research and development 14,461 15,656 32,865 36,092 General and administrative 9,229 4,547 17,528 8,633 Total operating expenses 23,690 20,203 50,393 44,725 Loss from operations Other income 975 538 Net loss $ $ $ $ Deemed dividend $ — $ — $ — $ Net loss attributable to common shareholders of Spero Therapeutics, Inc. $ $ $ $ Net loss per share attributable to common shareholders per share, basic and diluted $ $ $ $ Weighted average shares outstanding, basic and diluted: 29,675,399 20,..."
06/30/2021 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Press Release"
05/06/2021 8-K Quarterly results
03/11/2021 8-K Quarterly results
02/05/2021 8-K Quarterly results
01/19/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy